Khiron Enters Exclusive Partnership with RAPPI, Latin America's Largest Home Multi-Vertical App Platform

• Rappi is the largest home multi-Vertical app in Latin America, which received a USD 1 Billion investment from Softbank Group Corp. and Softbank Vision Fund, reaching unicorn status in 2019. Rappi operates in Brazil, Colombia, Mexico, Argentina, Chile, Costa Rica, Uruguay, Ecuador and Peru, which together represent a population of over 600 million people.
• Rappi's multi-vertical app provides digital banking and payment services, in addition to everything from food to pharmaceutical products, consumer package goods and courier services, with an average of more than 10 million active users monthly, according to research firm Apptopia.
• Expansive agreement starts with a 6-month exclusive distribution between Rappi and Khiron to introduce and distribute the Company's CPG product portfolio across Latin America through the Rappi platform.
• With the potential for future expansion, the partnership allows Khiron to introduce its CBD product lines in every country where Rappi has an established presence, leveraging a rapidly growing trend toward online sales and last-mile delivery. The agreement is expected to reduce overall product launch and, logistics costs, increasing availability and exposure to millions of consumers, and improving margins for both parties.
• The Kuida^TM in-app store within Rappi was launched in Colombia in May 2020. The companies intend to expand distribution through Rappi´s fast growing consumer base to Uruguay and Costa Rica, where Kuida has been approved, and other countries such as Brazil, Mexico and Chile, subject to regulatory approvals.

TORONTO, Sept. 3, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that it has entered into an exclusive distribution agreement with Rappi SAS, the leading Latin American last-mile multi-vertical platform that is backed with a USD 1 billion investment from Softbank Group Corp., and Softbank Vision Fund.  The expansive agreement comprises a 6-month exclusive distribution partnership between Rappi and Khiron to introduce and distribute the Company's CPG product portfolio across Latin America through the Rappi platform, starting with Kuida^TM, the Company's branded CBD skincare product line, with the potential to build on the partnership over time.

Beyond a standard vendor agreement, this expanded partnership introduces the Company's CBD-based Wellbeing products to millions of Rappi users across Latin America through its sophisticated technology and advanced, customer-centric marketing strategies. With the Kuida store already launched on Rappi in May 2020 for the Colombian market, distribution will be expanded to Uruguay and Costa Rica, where Kuida has been recently approved. The Company also intends to introduce its product line through Rappi's fast growing consumer base to countries such as Brazil, Mexico, Ecuador and Chile, subject to regulatory approvals.

Colombia's Rappi is the market leading multi-vertical application in Latin America with a presence in Brazil, Colombia, Mexico, Argentina, Chile, Ecuador, Costa Rica, Uruguay and Peru. Through its platform, customers buy products and services and receive home delivery across multiple categories, including, medical, health, grocery, restaurants, pharmacies, beverage and professional services among others. In addition, the application has a virtual wallet, RappiPay^TM, where users can make P2P transfers and payments.  Rappi has an average of more than 10 million active users monthly, according to research firm Apptopia, providing deliveries for almost 100,000 businesses in LatAm, including over 13 million deliveries in Colombia alone.

"Rappi is the delivery brand that everyone in Latin America knows and uses daily. The partnership with Rappi reduces our product launch and logistics costs and transforms our availability and exposure to millions of customers across the region. Rappi is the last-mile delivery brand that will help us bring Khiron product to more customers than ever before. We are proud to establish this first-of-its-kind partnership between these two companies, which are both industry leaders in LatAm, and were both founded by Colombians," comments Alvaro Torres, Khiron CEO and director.

"As the market for consumer cannabis products and services globalizes it is a natural fit for us to partner with Khiron to meet our app users´ needs. Like us, they are a recognized leader in the region, and an innovator in bringing quality products to market, "comments Simon Borrero, Rappi SAS CEO.

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, is fully authorized to manufacture and fill prescriptions for high- and low-THC medical cannabis in Colombia and has the first approved line of CBD cosmetic products on shelf in Colombia, and available in the United States and the United Kingdom.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

Related Links

https://www.khiron.ca/en/home